<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293146</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00256; ch18Weber4</org_study_id>
    <nct_id>NCT04293146</nct_id>
  </id_info>
  <brief_title>Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC</brief_title>
  <acronym>OPBC-02PREPEC</acronym>
  <official_title>Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy (OPBC-02/ PREPEC): A Pragmatic, Multicenter, Randomized, Superiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR)
      provides better Quality of Life (QoL) with respect to long-term (24 months) physical
      well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing
      mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR)
      provides better Quality of Life (QoL) with respect to long-term (24 months) physical
      well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing
      mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.The aim
      is to adhere to standard of care as much as possible to follow the pragmatic trial design to
      generate data that are applicable to today's practice. Therefore, surgeons are allowed to use
      their preferred Acellular Dermal Matrix (ADM), synthetic meshes, expanders and implants,
      thereby offering practitioners considerable leeway in deciding how to perform the procedure.
      For the same reason, both the one- and two-staged IBBR approaches are allowed when studying
      pre- versus sub-pectoral IBBR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">March 2033</completion_date>
  <primary_completion_date type="Anticipated">March 2032</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will objectively assess the results and complication of two surgical techniques and thus provide evidence to assess whether there are differences between these techniques.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>blinded outcome assessment for aesthetic results</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BREAST-Q scale</measure>
    <time_frame>within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)</time_frame>
    <description>compare the Quality of Life (QoL) with respect to long-term physical well-being (chest) after pre-pectoral or sub-pectoral IBBR. The BREAST-Q module specific to breast reconstruction version 2.0 consists of 13 independent scales covering health-related QoL domains and satisfaction domains. Each scale is scored to generate a numerical score on a scale from 0 (worst) to 100 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EQ-5D-5L questionnaire</measure>
    <time_frame>within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)</time_frame>
    <description>The 5-level version of the EQ-5D (EQ-5D-5L) consists of the EQ-5D descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/Depression (5 answer levels each: no problems, slight problems, moderate problems, severe problems and extreme problems), resulting in a 1-digit number that expresses the level for that dimension. The digits for each dimension are combined into a 5-digit number that describes the patient's health state and is subsequently converted into a preference-based quality of life weight (utility) using an algorithm derived from population-based studies. In addition, patients are asked to rate their health on a vertical visual analogue scale (EQ VAS), where the anchors are labelled with 'The best health you can imagine' and 'The worst health you can imagine'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>loss of expander or implant</measure>
    <time_frame>within 24 months of undergoing mastectomy and immediate reconstruction</time_frame>
    <description>compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of loss of expander or implant. Loss of expander or implant is defined as an unplanned surgical removal of expander/implant with or without immediate replacement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical complications</measure>
    <time_frame>within 24 months of undergoing mastectomy and immediate reconstruction</time_frame>
    <description>compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of surgical complications. The complications include: Wound dehiscence, Haematoma, Seroma, Implant/expander exposure/Extrusion, Implant/Expander rotation/malpositioning, Infection, Mastectomy skin flap necrosis, Capsular contraction, Lymphedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thromboembolic events</measure>
    <time_frame>within 24 months of undergoing mastectomy and immediate reconstruction</time_frame>
    <description>compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of thromboembolic events according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>over 24 months since mastectomy</time_frame>
    <description>compare patient satisfaction after pre-pectoral or sub-pectoral IBBR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>animation deformity</measure>
    <time_frame>before and 24 months after the mastectomy</time_frame>
    <description>compare animation deformity after pre-pectoral or sub-pectoral IBBR by using pictures from before and 24 months after the mastectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>capsular contracture</measure>
    <time_frame>before and 24 months after the mastectomy</time_frame>
    <description>compare capsular contracture after pre-pectoral or sub-pectoral IBBR by using pictures from before and 24 months after the mastectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aesthetic results</measure>
    <time_frame>before and 24 months after the mastectomy</time_frame>
    <description>compare aesthetic results after pre-pectoral or sub-pectoral IBBR assessed by photographs of the breast taken in a standardized way. They will be evaluated by an experienced investigator who is blinded for group assignment. The blinded outcome assessment team will be trained to enter data for the two most widely used semi-automatic software for objective aesthetic evaluation, the 'Breast Cancer Conservative Treatment cosmetic results' (BCCT.core)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival (RFS)</measure>
    <time_frame>until 10 years after mastectomy and IBBR.</time_frame>
    <description>RFS is defined as the time from randomization until the first documentation of any of the following events: local-regional occurrence or recurrence of invasive disease or ductal carcinoma in situ (DCIS), distant breast cancer metastasis, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aesthetic results evaluated by patients</measure>
    <time_frame>at baseline and after 24 months</time_frame>
    <description>evaluated by patients using a four point scale: excellent, good, regular, bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of operative procedures</measure>
    <time_frame>until 24 months after mastectomy</time_frame>
    <description>assess the burden on patients by total number of operative procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay (index hospitalization and overall)</measure>
    <time_frame>until 24 months after randomization</time_frame>
    <description>length of hospital stay (index hospitalization and overall) following randomization until discharge and the cumulative number of days the patient was hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of outpatient visits at the trial site and the emergency department</measure>
    <time_frame>from admission for mastectomy until 24 months after randomization</time_frame>
    <description>assess the burden on patients by total number of outpatient visits at the trial site and the emergency department</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aesthetic results evaluated by local physicians</measure>
    <time_frame>at baseline and after 24 months</time_frame>
    <description>evaluated by local physicians using a four point scale: excellent, good, regular, bad.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Breast Reconstruction</condition>
  <condition>Implant-Based Breast Reconstruction (IBBR)</condition>
  <arm_group>
    <arm_group_label>pre-pectoral IBBR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sub-pectoral IBBR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pre-pectoral IBBR</intervention_name>
    <description>The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.</description>
    <arm_group_label>pre-pectoral IBBR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sub-pectoral IBBR</intervention_name>
    <description>The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.</description>
    <arm_group_label>sub-pectoral IBBR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations prior to any trial specific
             procedures

          -  Patients undergoing NSM or SSM and IBBR in the therapeutic or risk-reducing Setting

          -  Ability to complete the Quality of Life questionnaires

        Exclusion Criteria:

          -  No indication for IBBR according to clinical judgment of the treating surgeon

          -  Skin flaps inadequate for pre-pectoral IBBR.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Weber, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Breast Surgery, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walter Weber, Prof. Dr. med</last_name>
    <phone>+41 61 328 61 49</phone>
    <email>walter.weber@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Haug, Prof. Dr. med</last_name>
    <phone>+41 61 265 7195</phone>
    <email>martin.haug@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon Chun, Dr. med</last_name>
      <phone>617-983-4774</phone>
      <email>ychun@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Reitsamer, Prof. Dr. med</last_name>
      <phone>+43 5 7255 27302</phone>
      <email>r.reitsamer@salk.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Fitzal, Prof. Dr. med</last_name>
      <phone>+43 1 40400 56460</phone>
      <email>florian.fitzal@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiasong Chen, Prof. Dr. med</last_name>
      <email>chenxiaosong0156@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KEM | Evang. Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherko Kümmel, Prof. Dr. med</last_name>
      <phone>+49 201 174 33002</phone>
      <email>S.Kuemmel@kem-med.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Heil, Prof. Dr. med</last_name>
      <phone>+49 6221 56 7901</phone>
      <email>joerg.heil@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltán Mátrai, Prof. Dr. med</last_name>
      <phone>+36 70 550 1268</phone>
      <email>matraidok@oncol.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>11281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana de Boniface, Prof. Dr. med</last_name>
      <email>jana.de-boniface@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Nigard</last_name>
      <email>linda.nigard@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Chiorescu, Dr. med</last_name>
      <phone>+46 702437309</phone>
      <email>amelia.chiorescu@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden Brustzentrum Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilario Fulco, Dr. med</last_name>
      <phone>+41 62 822 00 72</phone>
      <email>Ilario.Fulco@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau AG</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Sarlos, PD Dr. med</last_name>
      <phone>+41 62 838 50 65</phone>
      <email>dimitri.sarlos@ksa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel, Division of Breast Surgery</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Weber, Prof. Dr. med</last_name>
      <phone>+41 61 328 61 49</phone>
      <email>walter.weber@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Martin Haug, Prof. Dr. med</last_name>
      <phone>+41 61 265 7195</phone>
      <email>martin.haug@usb.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Plastische- und Handchirurgie, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihai Constantinescu, Prof. Dr. med</last_name>
      <phone>+41 31 632 8014</phone>
      <email>Mihai.Constantinescu@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lindenhof Bern</name>
      <address>
        <city>Bern</city>
        <zip>3011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Fischer, Dr. med</last_name>
      <phone>+41 31 3115822</phone>
      <email>thomas.fischer@centerclinic.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Holzbach, PD Dr. med</last_name>
      <phone>+41 52 723 76 76</phone>
      <email>thomas.holzbach@stgag.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Erni, Prof.Dr.med</last_name>
      <phone>+41 41 850 00 60</phone>
      <email>dominique.erni@hin.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum Fricktal</name>
      <address>
        <city>Rheinfelden</city>
        <zip>4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maik Hauschild, Dr. med.</last_name>
      <phone>+41 61 835 62 20</phone>
      <email>Maik.Hauschild@gzf.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Verstappen, Dr. med</last_name>
      <phone>+41 71 4943443</phone>
      <email>ralph.verstappen@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Viganello</city>
        <zip>6962</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Harder, Prof. Dr. med</last_name>
      <phone>+41 91 811 75 47</phone>
      <email>yves.harder@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brust-Zentrum Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Tausch, PD Dr. med</last_name>
      <phone>+41 44 533 81 00</phone>
      <email>c.tausch@brust-zentrum.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>China</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin-sparing mastectomy (SSM)</keyword>
  <keyword>nipple-sparing mastectomy (NSM)</keyword>
  <keyword>immediate breast reconstruction</keyword>
  <keyword>pre-pectoral breast implant</keyword>
  <keyword>sub-pectoral breast implant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

